Niflactol (Niflumic Acid)

Niflumic Acid, the active ingredient in Niflactol, is a fenamate presented as an oral formulation for oral use. It belongs to the nonsteroidal anti‑inflammatory drug class and is used to relieve pain and reduce inflammation in musculoskeletal and other inflammatory conditions by inhibiting cyclooxygenase enzymes and decreasing prostaglandin synthesis.

GNH USA supplies Niflactol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Niflumic Acid is indicated for conditions involving pain and inflammation within the musculoskeletal and rheumatologic disease spectrum.

- Pain relief: Provides analgesic effect in acute and chronic pain conditions. - Inflammation reduction: Decreases inflammatory response in soft tissue and joint disorders. - Musculoskeletal disorders: Improves mobility and reduces swelling in conditions such as osteoarthritis and rheumatoid arthritis.

Niflumic Acid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: Nausea, dyspepsia or abdominal pain. - Headache: Mild to moderate intensity. - Dizziness: Transient sensation of light‑headedness.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: Elevated liver enzymes or hepatitis. - Renal impairment: Acute kidney injury or reduced renal function. - Blood dyscrasias: Agranulocytosis, leukopenia or thrombocytopenia. - Anaphylaxis: Immediate hypersensitivity reaction.

When prescribing Niflumic Acid, clinicians should consider several precautionary measures to minimise risk.

- Assess renal function: Evaluate kidney status before initiation and monitor periodically. - Monitor hepatic enzymes: Check liver function tests due to potential hepatotoxicity. - Avoid in known hypersensitivity: Do not use in patients with previous allergic reactions to fenamates or other NSAIDs. - Use caution in elderly: Reduced renal clearance may increase adverse effects. - Concomitant anticoagulant use: Increase bleeding risk; monitor coagulation parameters. - Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture and direct sunlight.

Niflumic Acid can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Other NSAIDs: Combined use markedly raises risk of gastrointestinal bleeding. - Anticoagulants: Potentiates anticoagulant effect, increasing hemorrhage risk. - Lithium: May raise lithium serum concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: Additive risk of ulceration and gastrointestinal complications. - ACE inhibitors: May reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: Potential for decreased renal function and electrolyte imbalance.